Literature DB >> 3316032

Mechanisms of specific immunological unresponsiveness to bacterial lipopolysaccharides.

K L Elkins1, P W Stashak, P J Baker.   

Abstract

Low-dose priming of mice with Escherichia coli O113 lipopolysaccharide (LPS) results in the development of immunological memory, whereas low-dose priming with E. coli O55 LPS or Serratia marcescens LPS induces significant antigen-specific unresponsiveness. All three preparations of LPS induced proliferation of mouse splenocytes with similar time course and [3H]thymidine uptake. There was no correlation between the small amounts of serum antibody detected by enzyme-linked immunosorbent assay after low-dose priming and the subsequent generation of either memory or unresponsiveness. Further, the passive transfer of small amounts of LPS-specific antibody had no significant effect on the magnitude of the plaque-forming cell (PFC) response elicited after subsequent immunization. Reduction of the PFC response to E. coli O55 LPS occurred after low-dose priming of nu/nu (as well as nu/+) mice; however, unresponsiveness could not be generated in nu/nu mice by low-dose priming with S. marcescens LPS. Thus, although the development of low-dose unresponsiveness to S. marcescens LPS appears to involve T cells, the response of E. coli O55 LPS does not. Enhancement of the primary PFC response to S. marcescens LPS could be transferred with low-dose primed spleen cells depleted of Lyt-2+ T cells; this suggests that the magnitude of the PFC response to this preparation of LPS is negatively influenced by Lyt-2+ T cells and positively influenced by Lyt-2- spleen cells (i.e., L3T4+ T cells). These findings indicate that T cells appear to be involved in regulating the magnitude of the antibody response to some types of bacterial LPS.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3316032      PMCID: PMC260033          DOI: 10.1128/iai.55.12.3093-3102.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  45 in total

1.  Quantitative and qualitative studies on the primary antibody response to pneumococcal polysaccharides at ehe cellular level.

Authors:  P H Baker; P W Stashak
Journal:  J Immunol       Date:  1969-12       Impact factor: 5.422

2.  Application of transformations to normalize the distribution of plaque-forming cells.

Authors:  C F Gottlieb
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

3.  Molecular immunogenicity of bacterial lipopolysaccharide antigens: establishing a quantitative system.

Authors:  J A Rudbach
Journal:  J Immunol       Date:  1971-04       Impact factor: 5.422

4.  Regulation of antibody synthesis against Escherichia coli endotoxin. I. Suppressive effect of endogenously produced and passively transferred antibodies.

Authors:  S Britton; G Möller
Journal:  J Immunol       Date:  1968-06       Impact factor: 5.422

5.  Persistence of immunogenicity of two complex antigens retained in vivo.

Authors:  S Britton; T Wepsic; G Möller
Journal:  Immunology       Date:  1968-04       Impact factor: 7.397

6.  Activation of murine spleen cells by lipid A: negative modulation of lipid A mitogenic activity by O-antigen polysaccharide.

Authors:  S W Vukajlovich; D C Morrison
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

7.  Use of erythrocytes sensitized with purified pneumococcal polysaccharides for the assay of antibody and antibody-producing cells.

Authors:  P J Baker; P W Stashak; B Prescott
Journal:  Appl Microbiol       Date:  1969-03

8.  Activation of T and B lymphocytes in vitro. I. Regulatory influence of bacterial lipopolysaccharide (LPS) on specific T-cell helper function.

Authors:  D Armerding; D H Katz
Journal:  J Exp Med       Date:  1974-01-01       Impact factor: 14.307

9.  Differentiation of T cells induced by preparations from thymus and by nonthymic agents.

Authors:  M P Scheid; M K Hoffmann; K Komuro; U Hämmerling; J Abbott; E A Boyse; G H Cohen; J A Hooper; R S Schulof; A L Goldstein
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

10.  Genetic control of the antibody response to type 3 pneumococcal polysaccharide in mice. I. Evidence that an X-linked gene plays a decisive role in determining responsiveness.

Authors:  D F Amsbaugh; C T Hansen; B Prescott; P W Stashak; D R Barthold; P J Baker
Journal:  J Exp Med       Date:  1972-10-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes.

Authors:  P J Baker
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

2.  Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A.

Authors:  P J Baker; J R Hiernaux; M B Fauntleroy; B Prescott; J L Cantrell; J A Rudbach
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

3.  T-cell modulation of the antibody response to bacterial polysaccharide antigens.

Authors:  C E Taylor; R Bright
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

4.  Prior exposure to subimmunogenic amounts of some bacterial lipopolysaccharides induces specific immunological unresponsiveness.

Authors:  K L Elkins; P W Stashak; P J Baker
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

5.  Specific immunological unresponsiveness to bacterial lipopolysaccharides develops in a cyclic manner.

Authors:  K L Elkins; P W Stashak; P J Baker
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

6.  Characterization of the immunodeficiency of RIIIS/J mice: immune response to polysaccharide antigens.

Authors:  J R Hiernaux; P J Baker; S J McEvoy; P W Stashak; M B Fauntleroy; E A Goidl
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

7.  Molecular structures that influence the immunomodulatory properties of the lipid A and inner core region oligosaccharides of bacterial lipopolysaccharides.

Authors:  P J Baker; T Hraba; C E Taylor; P W Stashak; M B Fauntleroy; U Zähringer; K Takayama; T R Sievert; X Hronowski; R J Cotter
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.